20 May 2013
Keywords: antisoma, asa404, fails, ovarian, cancer, trial, uk-based
Article | 23 July 2007
UK-based cancer drug developer Antisoma says that new data from a Phase II trial of its chemotherapy adjuvant ASA404 (formerly ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 July 2007
© 2013 thepharmaletter.com